Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the existing 20 natural amino acids, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. Ambrx is based in the USA in La Jolla, CA.

Latest News Entry
Chinese Consortium Enters into Agreement to Acquire Ambrx

The transaction is expected to close in the second quarter of 2015 ...

all portfolio news